[1] |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017[J]. CA Cancer J Clin, 2017,67(1): 7-30.
|
[2] |
Barroso-Sousa R, Silva DD, Alessi JV, et al. Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives[J]. Ecancermedicalscience, 2016, 10: 609.
|
[3] |
Gazet JC, Markopoulos C, Ford HT, et al. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer[J]. Lancet, 1988, 1(8587): 679-681.
|
[4] |
Chiba A, Hoskin TL, Heins CN, et al. Trends in neoadjuvant endocrine therapy use and impact on rates of breast conservation in hormone receptor-positive breast cancer: a national cancer data base study[J]. Ann Surg Oncol, 2017, 24(2): 418-424.
|
[5] |
Gradishar WJ, Anderson BO, Balassanian R, et al. NCCN guidelines insights breast cancer, version 1.2016[J]. J Natl Compr Canc Netw, 2015,13(12): 1475-1485.
|
[6] |
Ellis MJ, Ma C. Letrozole in the neoadjuvant setting: the P024 trial[J]. Breast Cancer Res Treat, 2007,105 Suppl 1: 33-43.
|
[7] |
Ellis MJ, Suman VJ, Hoog J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American College of Surgeons Oncology Group Z1031 Trial (Alliance)[J]. J Clin Oncol, 2017,35(10): 1061-1069.
|
[8] |
Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial[J]. J Clin Oncol, 2005,23(22): 5108-5116.
|
[9] |
Spring LM, Gupta A, Reynolds KL, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016,2(11): 1477-1486.
|
[10] |
Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase Ⅱ neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031[J]. J Clin Oncol, 2011,29(17): 2342-2349.
|
[11] |
Di LA, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J]. J Clin Oncol, 2010,28(30): 4594-4600.
|
[12] |
Kuter I, Gee JM, Hegg R, et al. Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase Ⅱ study[J]. Breast Cancer Res Treat, 2012,133(1): 237-246.
|
[13] |
Ellis MJ, Llombart-Cussac A, Feltl D, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase Ⅱ FIRST study[J]. J Clin Oncol, 2015, 33(32): 3781-3787.
|
[14] |
Lerebours F, Rivera S, Mouret-Reynier MA, et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609)[J]. Cancer, 2016,122(19): 3032-3040.
|
[15] |
Gazet JC, Ford HT, Gray R, et al. Estrogen-receptor-directed neoadjuvant therapy for breast cancer: results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C (MMM) chemotherapy[J]. Ann Oncol, 2001,12(5): 685-691.
|
[16] |
Torrisi R, Bagnardi V, Pruneri G, et al. Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer[J]. Br J Cancer, 2007,97(6): 802-808.
|
[17] |
Torrisi R, Bagnardi V, Rotmensz N, et al. Letrozole plus GnRH analogue as preoperative and adjuvant therapy in premenopausal women with ER positive locally advanced breast cancer[J]. Breast Cancer Res Treat, 2011,126(2): 431-441.
|
[18] |
Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2012,13(4): 345-352.
|
[19] |
Barbie TU, Ma C, Margenthaler JA. Management of premenopausal women with neoadjuvant endocrine therapy: a single-institution experience[J]. Ann Surg Oncol, 2015,22(12): 3861-3865.
|
[20] |
Shimizu D, Ishikawa T, Tanabe M, et al. Preoperative endocrine therapy with goserelin acetate and tamoxifen in hormone receptor-positive premenopausal breast cancer patients[J]. Breast Cancer, 2014, 21(5): 557-562.
|
[21] |
Gradishar W, Salerno KE. NCCN guidelines update: breast cancer [J]. J Natl Compr Canc Netw, 2016,14(5 Suppl): 641-644.
|
[22] |
Alba E, Calvo L, Albanell J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-Ⅱ study[J]. Ann Oncol, 2012,23(12): 3069-3074.
|
[23] |
Palmieri C, Cleator S, Kilburn LS, et al. NEOCENT: a randomised feasibility and translational study comparing neoadjuvant endocrine therapy with chemotherapy in ER-rich postmenopausal primary breast cancer[J]. Breast Cancer Res Treat, 2014,148(3): 581-590.
|
[24] |
Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al. Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase Ⅱb/Ⅲ trial to investigate optimal duration of preoperative endocrine therapy[J]. BMC Cancer, 2008,8: 62.
|
[25] |
Fontein DB, Charehbili A, Nortier JW, et al. Efficacy of six month neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients--a phase Ⅱ trial[J]. Eur J Cancer, 2014,50(13): 2190-2200.
|
[26] |
Llombart-Cussac A, Guerrero Á, Galán A, et al. Phase Ⅱ trial with letrozole to maximum response as primary systemic therapy in postmenopausal patients with ER/PgR[+] operable breast cancer[J]. Clin Transl Oncol, 2012,14(2): 125-131.
|
[27] |
Carpenter R, Doughty JC, Cordiner C, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery[J]. Breast Cancer Res Treat, 2014,144(3): 569-576.
|
[28] |
Jackisch C, Harbeck N, Huober J, et al. 14th St. Gallen International Breast Cancer Conference 2015: evidence, controversies, consensus- primary therapy of early breast cancer: opinions expressed by German experts[J]. Breast Care (Basel), 2015,10(3): 211-219.
|
[29] |
Cortazar P, Zhang L, Untch M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172.
|
[30] |
Iwamoto T, Katagiri T, Niikura N, et al. Immunohistochemical Ki67 after short-term hormone therapy identifies low-risk breast cancers as reliably as genomic markers[J]. Oncotarget, 2017,8(16): 26 122-26 128.
|
[31] |
Kurozumi S, Matsumoto H, Hayashi Y, et al. Power of PgR expression as a prognostic factor for ER-positive/HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index[J]. BMC Cancer, 2017, 17(1): 354.
|
[32] |
Kutomi G, Mizuguchi T, Satomi F, et al. Current status of the prognostic molecular biomarkers in breast cancer: A systematic review[J]. Oncol Lett, 2017,13(3): 1491-1498.
|
[33] |
Ueno T, Masuda N, Yamanaka T, et al. Evaluating the 21-gene assay recurrence score as a predictor of clinical response to 24 weeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer[J]. Int J Clin Oncol, 2014, 19(4): 607-613.
|
[34] |
Parker JS, Mullins M, Cheang MC, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes[J]. J Clin Oncol, 2009, 27(8): 1160-1167.
|
[35] |
Gnant M, Filipits M, Greil R, et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone[J]. Ann Oncol, 2014, 25(2): 339-345.
|